Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes

Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes

Abstract Background Rheumatoid arthritis (RA) is a chronic autoimmune disease. We previously revealed that the natural compound artemisitene (ATT) exhibits excellent broad anticancer activities without toxicity on normal tissues. Nevertheless, the effect of ATT on RA is undiscovered. Herein, we aim...

Full description

Bibliographic Details
Main Authors: Jian Chen, Xian Lin, Juan He, Dandan Liu, Lianhua He, Miaomiao Zhang, Huijie Luan, Yiping Hu, Cheng Tao, Qingwen Wang
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:Clinical and Translational Medicine
Subjects:
artemisitene
fibroblast‐like synoviocytes
ICAM2
METTL3
rheumatoid arthritis
Online Access:https://doi.org/10.1002/ctm2.1148

Internet

https://doi.org/10.1002/ctm2.1148

Similar Items